Last: | $106.44 |
---|---|
Change Percent: | 0.21% |
Open: | $106.32 |
Close: | $106.44 |
High: | $106.68 |
Low: | $105.895 |
Volume: | 1,079,694 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$106.44 | $106.32 | $106.44 | $106.68 | $105.895 | 1,079,694 | 07-02-2024 |
$106.54 | $106.58 | $106.54 | $107.62 | $106.3 | 1,194,262 | 07-01-2024 |
$106.46 | $106.75 | $106.46 | $107.12 | $106.235 | 1,516,862 | 06-28-2024 |
$106.55 | $106.65 | $106.55 | $106.78 | $106.11 | 1,268,678 | 06-27-2024 |
$107.07 | $106.76 | $107.07 | $107.34 | $106.53 | 1,547,216 | 06-26-2024 |
$107.37 | $107.22 | $107.37 | $107.4 | $106.79 | 819,381 | 06-25-2024 |
$106.95 | $107.47 | $106.95 | $107.67 | $106.91 | 1,551,184 | 06-24-2024 |
$105.22 | $105.39 | $105.22 | $105.71 | $104.44 | 1,302,106 | 06-21-2024 |
$105.74 | $104.66 | $105.74 | $105.85 | $104.4 | 1,285,660 | 06-20-2024 |
$104.94 | $105.33 | $104.94 | $105.57 | $104.86 | 1,051,803 | 06-19-2024 |
$104.94 | $105.33 | $104.94 | $105.57 | $104.86 | 1,051,803 | 06-18-2024 |
$104.93 | $104.44 | $104.93 | $105.155 | $104.23 | 997,144 | 06-17-2024 |
$105.72 | $106.66 | $105.72 | $106.77 | $104.95 | 2,565,119 | 06-14-2024 |
$106.02 | $105.78 | $106.02 | $106.19 | $104.94 | 1,077,649 | 06-13-2024 |
$105.55 | $106.33 | $105.55 | $106.37 | $105.52 | 1,938,974 | 06-12-2024 |
$104.51 | $104.98 | $104.51 | $104.98 | $104.205 | 1,523,217 | 06-11-2024 |
$105.4 | $105.07 | $105.4 | $105.46 | $104.7811 | 1,255,773 | 06-10-2024 |
$105.33 | $106.195 | $105.33 | $106.215 | $105.26 | 849,684 | 06-07-2024 |
$106.13 | $105.68 | $106.13 | $106.46 | $105.65 | 1,031,381 | 06-06-2024 |
$105.36 | $105.47 | $105.36 | $105.59 | $105.06 | 1,109,131 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio PR Newswire In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demons...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo PR Newswire Secondary endpoint data for estimated glomerular filtration rate (eGF...